Search

Your search keyword '"Brunet, Salut"' showing total 11 results
Start Over Author "Brunet, Salut" Journal british journal of haematology
11 results on '"Brunet, Salut"'

1. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

Author

Sánchez-García, Joaquín, del Cañizo, Consuelo, Lorenzo, Ignacio, Nomdedeu, Benet, Luño, Elisa, de Paz, Raquel, Xicoy, Blanca, Valcárcel, David, Brunet, Salut, Marco-Betes, Victor, García-Pintos, Marta, Osorio, Santiago, Tormo, Mar, Bailén, Alicia, Cerveró, Carlos, Ramos, Fernando, Diez-Campelo, María, Such, Esperanza, Arrizabalaga, Beatriz, Azaceta, Gemma, Bargay, Joan, Arilla, María J., Falantes, José, Serrano-López, Josefina, and Sanz, Guillermo F.

Published
2014
Full Text
View/download PDF

2. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols

Author

Ribera, Josep-María, García, Olga, Fernández-Abellán, Pascual, Lavilla, Esperanza, Bernal, María-Teresa, González-Campos, José, Brunet, Salut, Monteserín, María-Carmen, Montesinos, Pau, Sarrá, Josep, Calbacho, Maria, Álvarez-Larrán, Alberto, Tormo, Mar, and Oriol, Albert

Published
2012
Full Text
View/download PDF

8. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation

Author

Gallardo, David, Aróstegui, Juan Ignacio, Balas, Antonio, Torres, Antonio, Caballero, Dolores, Carreras, Enric, Brunet, Salut, Jiménez, Antonio, Mataix, Rodolfo, Serrano, David, Vallejo, Carlos, Sanz, Guillermo, Solano, Carlos, Rodríguez-Luaces, Marta, Marín, Julián, Baro, Julio, Sanz, César, Román, Jose, González, Marcos, Martorell, Jaume, Sierra, Jorge, Martín, Carmen, de la Cámara, Rafael, and Grañena, Albert

Published
2001

9. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies

Author

Brunet, Salut, Urbano-Ispizua, Alvaro, Ojeda, Emilio, Ruiz, Dolores, Moraleda, José Ma., Díaz, Miguel Angel, Caballero, Dolores, Bargay, Joan, de la Rubia, Javier, Solano, Carlos, Zuazu, Javier, Diez, José Luis, de la Serna, Javier, Espigado, Idelfonso, Alegre, Adrián, Torres, J. Pio, Jurado, Manuel, Fernández, Manuel, Vivancos, Pilar, Carreras, Enric, Hernández, Fernando, Maldonado, Juan, Sierra, Jorge, and Rozman, Ciril

Published
2001

11. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.

Author

Bataller A, Oñate G, Diaz-Beyá M, Guijarro F, Garrido A, Vives S, Tormo M, Arnan M, Salamero O, Sampol A, Coll R, Vall-Llovera F, Oliver-Caldés A, López-Guerra M, Pratcorona M, Zamora L, Villamon E, Roué G, Blanco A, Nomdedeu JF, Colomer D, Brunet S, Sierra J, and Esteve J

Subjects
Adolescent, Adult, Aged, Disease-Free Survival, Europe, Female, Humans, Male, Middle Aged, Neoplasm, Residual, Nucleophosmin, Survival Rate, Induction Chemotherapy, Leukemia, Myeloid, Acute blood, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Mutation, Neoplasm Proteins genetics, Nuclear Proteins genetics
Abstract

In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) with NPM1 mutations (ELNfav NPM1 AML), although a proportion of these patients will relapse. Given the prognostic importance of measurable residual disease (MRD), CETLAM-12 considered a pre-emptive intervention in patients with molecular failure (MF). We analyzed 110 ELNfav NPM1 AML patients achieving complete remission (CR) after induction chemotherapy. Two-year cumulative incidence of relapse (CIR), overall survival (OS) and leukaemia-free survival (LFS) were 17%, 81·5% and 82%, respectively. Forty-six patients required additional therapy for MF (n = 33) or haematological relapse (HemR; n = 13), resulting in a molecular LFS (molLFS) and a cumulative incidence of MF at two years of 61% and 38% respectively. Two-year OS for these 46 patients was 66%, with a different outcome between patients with MF (86%) and HemR (42%) (P = 0·002). Quantitative NPM1 detection at different timepoints was predictive of molLFS; an MRD ratio (NPM1mut/ABL1 × 100) cut-off of 0·05 after first consolidation identified two cohorts with a two-year molLFS of 77% and 40% for patients below and above 0·05, respectively. In conclusion, MRD-based pre-emptive intervention resulted in a favourable outcome for ELNfav NPM1 AML patients., (© 2020 British Society for Haematology and John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results